MEDPHARM - Key Persons
Job Titles:
- Senior Director of Sales & Marketing
Daniel Morland started at MedPharm in 2018 as a Senior Business Development Manager and returned in 2024 as Senior Director of Sales & Marketing. He brings with him more than 15 years of experience in the pharmaceutical industry, with an emphasis on contract services. Prior to joining MedPharm, Daniel worked in sales and management roles at organizations such as Reading Scientific Services, Butterworth Laboratories, and Simbec-Orion. He holds an MBA from the University of Warwick Business School.
Job Titles:
- Member of the Board
- General Partner of Ampersand Capital Partners
David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, David was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Bioventus, Detector Technologies, Gyros Protein Technologies and MedPharm. His prior Board Directorships have included Avista Pharma, ACLARA Biosciences, Assay Designs, NOVEX, Roadrunner Pharmacy and Signature Genomic Laboratories. David currently heads Ampersand's European office, which is based in Amsterdam.
Job Titles:
- Senior Vice President of Pharmaceutical Development
Charles Evans has been with MedPharm for over 15 years and has been heavily involved in evolving and refining the company's rigorous approach to formulation development. Charles has many years of expertise in the successful development of robust commercial products across all types of topical, inhalation and transdermal formulations. Moreover, he played a key role in the development of MedPharm's proprietary MedSpray® technology that is currently under license to customers to enhance their products' performance. He obtained his PhD at the University of Hertfordshire for the development of a novel dynamic spray formulation for the treatment of Athlete's foot.
Jon Lenn has direct responsibility for MedPharm's operations in the United States based out of Durham, North Carolina. Since joining in 2015 he has led MedPharm's development of cutting edge performance models for assessing penetration and activity of clients' products targeted towards key biochemical pathways. He has over 15 years' experience in developing dermatological projects with Connetics, Stiefel and GSK and has been directly involved with the development and approval of 8 products. He received his PhD on the topical delivery of macromolecules from the University of Reading.
Job Titles:
- Chief Executive Officer
- VP of Business Development
Lynn Allen joined MedPharm as VP of Business Development in 2019 and moved into the role of Chief Executive Officer in 2024. She has more than 25 years of experience in sales and management, focusing on contract services for sterile and non-sterile dosage forms. Prior to joining MedPharm, Lynn worked in sales and management roles for DPT/Mylan and Jubilant HollisterStier. She holds an MBA from the University of Chicago.
Job Titles:
- Vice President of Quality Assurance
Marta joined MedPharm as Vice President of Quality Assurance in 2020. She brings with her over thirty years of diverse process and product experience in the biotech and pharmaceutical industry working in manufacturing, QC, Validation and QA areas. She has held leadership roles for companies like Cambrex, Abbott, MedImmune, DPT and most recently Torrent Pharma. Marta will be responsible for advancing the Quality Systems in the US for GLP and cGMP operations. Marta has a B.S in Chemical Engineering from the University of Puerto Rico, Mayaguez.
Job Titles:
- Senior Director of Human Resources
Melanie Gubeno joined MedPharm in July 2021 as our Senior Director of Human Resources. With over 20 years of experience, she has served in a variety of HR positions and joins MedPharm after leading HR teams with increasing responsibility at Harland Clarke Corporation, and most recently at Ontic. Melanie plays a critical role in maturing our employee management systems and benefit programs to offer a best-in-class approach and rewards package. Melanie has a Bachelor of Arts in Business Administration from Ashland University (Summa Cum Laude), an MBA from Capital University and the following HR accreditations (SPHR and SHRM-SCP).
Job Titles:
- Member of the Board
- Senior Managing Director
Minor Hinson is a Senior Managing Director and the Chief Investment Officer of Bourne Partners Strategic Capital ("BPSC"). Over the course of his career, Minor has been involved in financial transactions totaling over $10 billion, including venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side and buy-side M&A transactions (both large cap and middle market) and other corporate finance advisory assignments. Minor has also served on the Board of Directors for a number of companies over his career. Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill.
Job Titles:
- Chairman of the Board
- Ampersand As an Operating Partner
Patrick joined Ampersand as an Operating Partner in 2018 and has been CEO of three Ampersand portfolio companies including Alcami, TriPharm Services and Avista Pharma. He currently serves as Chairman of the Board of Alcami and Chairman of the Board of ANI Pharmaceuticals. He has been involved in other Ampersand portfolio companies, serving as Chairman of Brammer Bio and a Director at MedPharm, Ltd. He has extensive experience directing pharmaceutical manufacturing and lab operations on a global scale in fill finish, API, specialty pharmaceutical, formulation, manufacturing, and analytical contract development organizations. Over the course of his 42-year career in the healthcare industry, Patrick has been CEO of six pharma companies and served as a company director in fifteen healthcare organizations.
Since completing his PhD in 1987 under the supervision of Professor Brian Barry, Adrian has worked in academia at the University of Bradford and more recently at Reading. His research focusses on topical and transdermal drug delivery but his work on novel formulations and biomacromolecule delivery extends to mucosal tissue, ocular and oral routes. He has published over 150 research articles (Adrian Williams - Google Scholar) alongside reviews, chapters and books - most recently The Art and Science of Dermal Formulation Development - 1st Edition - (routledge.com) co-authored with MedPharm Co-Founder, Prof. Marc Brown. In addition to numerous invited lectures at global academic conferences, he has been a member of advisory boards for various companies and acted as an expert witness in litigation matters in the UK, Europe and USA.
Job Titles:
- Member of the Scientific Advisory Committee
Clive Page is a member of the Scientific Advisory Committee at MedPharm and Professor of Pharmacology at King's College London. He is Co-Founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed company developing new drugs for the treatment of respiratory diseases and has held Non-Executive Board positions at Stirling Products Ltd, Immune Regulation Ltd and Babraham Biotechnology Ltd. Mr Page was awarded an OBE for "Services to Pharmacology" in 2017 and currently serves as a Non-Executive Director of PreP Biopharma and as Non-Executive Chairman of the Board of EpiEndo.
Job Titles:
- Chairman of Scientific Advisory Committee & Co - Founder
Prof. Marc Brown co-founded MedPharm in August 1999, was CSO until 2020, Board Director until 2024, and he remains Chair of MedPharm's Scientific Advisory Committee. Marc was instrumental in establishing MedPharm's principles and ethos, and has been a guiding force behind many of MedPharm's scientific developments, innovations and intellectual property. To date, he has been involved in the pharmaceutical development of over 60 locally applied medicinal products that are on the market in Europe, America and Japan. Currently he acts as CSO to Mosanna Therapeutics AG supporting the development of a nasally delivered sleep apnoea medicine, advises numerous pharmaceutical companies and acts as an expert witness in patent disputes across the UK, EU and USA. Prior to establishing MedPharm he was an academic in the Pharmacy Departments at King's College London (KCL) and the University of Hertfordshire and has visiting/honorary professorships at the Universities of Reading, Hertfordshire and King's College London; he was awarded the status of Professor Emeritus in 2022. He has co-supervised over 50 PhD students to success, and has co-authored 2 books, over 200 publications, 30 book chapters and 26 patents describing his research interests which lie mainly in drug delivery to the skin, nail, eye and airways.
Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London. He has held academic posts at the University of California, San Francisco and the University of Geneva. In 2004, he joined the University of Bath as Professor of Pharmaceutical Sciences. Professor Guy's research focuses on skin barrier function characterisation, topical and transdermal formulation development and optimisation, non-invasive biosensing and the prediction and assessment of skin penetration and topical bioavailability. He has published 380 peer-reviewed articles (H-index = 75; >21,000 citations) and 70 book chapters. He has co-authored one book and co-edited 7 others. He is also co-inventor of 12 patents. In 2016, Professor Guy was awarded the degree of Doctor of Science from the University of Oxford and the Maurice-Marie Janot Award from APGI for original and innovative research in pharmaceutics, biopharmaceutics and pharmaceutical technology. Having received the Founders' Award of the Controlled Release Society (CRS) in 2013, Professor Guy was the first recipient of the CRS Transdermal Delivery Kydonieus Foundation Award in 2018. In that same year, he completed a year's secondment at the European Medicines Agency as a National Expert in the area of regulatory science. Since 2013, research in Professor Guy's laboratory has been funded continuously by grants from the US FDA.
Job Titles:
- Member of the Board
- Partner of Ampersand Capital Partners
Trevor Wahlbrink is a Partner of Ampersand Capital Partners, which he joined in 2012. Prior to Ampersand, Mr. Wahlbrink was an investment banker at Morgan Keegan and Covington Associates where he advised on merger and acquisition and capital raising transactions for middle market healthcare and technology companies. Mr. Wahlbrink currently serves on the Boards of Directors of Confluent Medical and MedPharm. His prior Board Directorships have included Avista Pharma, Corpus Medical, Elite One Source Nutritional Services and ETE Medical. Mr. Wahlbrink is based in Ampersand's Wellesley, MA USA offices.